Aurobindo Pharma Ltd (AUROPHARMA) — share price & stock analysis

Market cap

₹90,175 Cr

P/E

25.4×

ROE

10.1%

vs own 10-yr valuation

96th pctile

Book value / share

₹652

EPS (TTM)

₹61.1

10-yr median P/E

17.7×

Revenue (FY26)

₹33,653 Cr

Profit after tax (FY26)

₹3,503 Cr

Weinstein stage

Stage 2 (30 weeks)

Data as of

1 July 2026

3 of the 6 things we track are currently moving the right way — most of the dashboard is turning up.

Where the levels actually stand: ROCE 13% — decent; effectively no debt; margins mid-band. Momentum says which way things are moving; these say where they are.

Read this number for what it is: it measures the DIRECTION of change, not the quality of the business. A mediocre business getting better scores high here; a great one having a soft quarter scores low. Profit, sales and margins count double.

The price has run ahead of the profits

Since Mar 2016, the stock is up 113% while earnings per share grew 76%. The difference is re-rating — investors paying more for the same rupee of profit.pricettm_eps

That works until it doesn’t: from here, earnings have to do the lifting, because the multiple has already done its part.

Today’s P/E of 25.4× means the market is paying up — this is the expensive end of its own 10-year history (96th percentile).pe_ratio

Price is the weekly close (₹). EPS is trailing-twelve-month profit per share, anchored on Screener's own snapshots; between snapshots it is filled from price ÷ P/E (an exact identity), and any fill straying more than 18% from the neighbouring snapshots is dropped rather than shown. The lower panel is the P/E — what the market pays per rupee of profit; the dotted line is its long-run median (17.7×).

The price is in a confirmed uptrend — 30 weeks and counting

Stock prices move through four repeating stages: basing (1), advancing (2), topping (3) and declining (4). This one is in Stage 2: advancing, 30 weeks in, confirmed.stage

The price sits above its rising 200-day average (₹1,306 today) — trends like this persist more often than they reverse, which is why the system rides them instead of guessing the top.dma_200

Beating NIFTY 500 for 24 weeks — relative strength is the market’s live opinion, and right now it is on this stock’s side.rs_mansfield

What would end it: two Friday closes in a row below the 200-day line. That is the house exit rule — mechanical, no debates.dma_200

A lumpy ride — no clean trend in profits

Over 12 years, sales went from ₹8,089 Cr to ₹33,653 Cr (about 13% a year), and profit from ₹1,169 Cr to ₹3,503 Cr.revenuenet_profit

Sales have gone quiet — growth has stalled

Mar 26 sales were ₹8,853 Cr, up 6% on the same quarter last year.revenue

That makes 11 quarters of growth in a row — this is a trend, not a blip.revenue

Margins have been rebuilt — 14.9% in FY23 to 20.3% now

Of every ₹100 of sales, the company keeps ₹19.8 as operating profit (a year ago it kept ₹21.0).opm_pct

Zoom out and this is the page's quiet hero: annual operating margin bottomed at 14.9% in FY23 and has been rebuilt to 20.3% — that recovery, not sales alone, is what powers the profit growth elsewhere on this page.operating_profit

The gross margin barely moved (59% → 61%), so the change came from running costs — overheads are growing faster than sales.gpm_pctopm_pct

Profit is treading water

Mar 26 profit after tax was ₹921 Cr, up 2% year on year.net_profit

The profits are real — they turn into cash

Over the last 5 profitable years, the business reported ₹14,731 Cr of profit and collected ₹19,289 Cr of operating cash — about 131% conversion.operating_cash_flownet_profit

One asterisk on that strength: suppliers are being paid 34 days later than a year ago (117 → 151 days). Cash flattered by stretching payables is real cash — but it is borrowed timing, not extra earning power.payable_days

The cash cycle is stretching — more money stuck in the pipeline

One rupee now takes about 252 days to go out the door as materials and come back as collected cash — up from 244 days the year before.cash_conversion_cycle

The biggest mover: suppliers being paid later (117 → 151 days).payable_days

Building hard — new capacity is under construction

The productive asset base has gone from ₹2,722 Cr (FY14) to ₹19,611 Cr, with another ₹3,009 Cr of capacity under construction right now.fixed_assetscwip

Work-in-progress is 15% of the existing asset base — that is a serious bet on future demand. Capacity like this shows up in sales with a lag; it is tomorrow’s growth being paid for today.cwip

The build is self-funded: the last 3 years' investing outflow (₹9,567 Cr) fits inside the operating cash the business generated (₹11,886 Cr).investing_cash_flowoperating_cash_flow

Almost no debt — this company cannot be killed by a bad year

For every ₹100 shareholders have put in (and left in), the company has borrowed ₹21 — total borrowings have grown from ₹3,769 Cr to ₹8,073 Cr over the window.borrowings

Every ₹100 kept in the business earns ₹13 — decent, not special

Return on capital employed is 13.0% (a year ago: 14.0%). This is the single best test of business quality: what the company earns on the money it keeps.roce_pct

The owners aren’t moving

Promoters hold 51.8%, essentially unchanged. Foreign funds own 15.2%, domestic funds 25.8%.promoters_pctfiis_pctdiis_pct

Meanwhile foreign funds have been the sellers — from 24.1% to 15.2% over the window. Someone on the other side of the table disagrees; both sides count.fiis_pct

Worth studying deeper — with eyes open

The numbers lean positive, and the price already assumes the good news continues.

Best thing in the data: cash generation rising (₹3,925 Cr → ₹5,526 Cr).operating_cash_flow

One dissent worth hearing: our valuation lens reads negative — “its fair-value math says the price sits about 39% above what the numbers justify”. When a lens disagrees with the committee, it is usually pointing at the thing that breaks first.

Machine-written research from Screener data — every number traces to its source column. Sector Alpha is not a SEBI-registered investment adviser; nothing here is a recommendation to buy or sell. Not investment advice.

Straight answers from the data